| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH COMMUNICATION |
1 From the Wageningen Centre for Food Sciences and the Division of Human Nutrition, Wageningen University, Wageningen, Netherlands (AM-B and PV), and the Department of Pediatrics and Neurology, University Medical Center Nijmegen, Nijmegen, Netherlands (KJAL and HJB)
Background: Before dietary folate is absorbed, polyglutamate folates are deconjugated to monoglutamates by folylpoly-
-glutamyl carboxypeptidase in the small intestine. The 1561T allele of the glutamate carboxypeptidase II gene (GCPII), which codes for folylpoly--glutamyl carboxypeptidase, may impair intestinal absorption of dietary folates.
Objective: Our aim was to study the bioavailability of polyglutamyl folic acid relative to that of monoglutamyl folic acid across GCPII 1561 genotypes.
Design: In a randomized study, 180 healthy adults aged 50–75 y received 323 nmol monoglutamyl folic acid/d (n = 59), 262 nmol heptaglutamyl folic acid/d (n = 61), or placebo (n = 60) for 12 wk. Genotypes were assessed after the intervention. The bioavailability of heptaglutamyl folic acid relative to that of monoglutamyl folic acid was calculated by using the changes in serum folate concentration in the treatment groups, after correction for changes in the placebo group and for the administered dose.
Results: No subjects with the TT genotype were encountered. At baseline, serum and erythrocyte folate concentrations were higher (P < 0.05) in subjects with the CT genotype [16.3 nmol/L (geometric 
; 95% CI: 13.7, 19.3 nmol/L) and 863 nmol/L (735, 1012 nmol/L), respectively; n = 19] than in subjects with the CC genotype [13.7 (13.1, 14.3) and 685 (652, 721) nmol/L, respectively; n = 161]. Baseline homocysteine concentrations were not significantly different between genotypes. The bioavailability of heptaglutamyl folic acid relative to that of monoglutamyl folic acid was not significantly different between subjects with the CC (64%; 52%, 76%) and CT genotypes (70%; 49%, 91%).
Conclusions: The 1561T allele of the GCPII gene does not impair the bioavailability of polyglutamyl folic acid. However, the allele is associated with higher folate status. This association may be explained by yet unidentified factors controlling the expression of the GCPII gene.
Key Words: Folate bioavailability • polyglutamyl folic acid • serum folate • erythrocyte folate • plasma homocysteine • glutamate carboxypeptidase II gene 1561C
T polymorphism • genetics
This article has been cited by other articles:
|
|
 |
|
  E. P Quinlivan and J. F Gregory III Reassessing folic acid consumption patterns in the United States (1999 2004): potential effect on neural tube defects and overexposure to folate Am. J. Clinical Nutrition, December 1, 2007; 86(6): 1773 - 1779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H Halsted, D. H Wong, J. M Peerson, C. H Warden, H. Refsum, A D. Smith, O. K Nygard, P. M Ueland, S. E Vollset, and G. S Tell Relations of glutamate carboxypeptidase II (GCPII) polymorphisms to folate and homocysteine concentrations and to scores of cognition, anxiety, and depression in a homogeneous Norwegian population: the Hordaland Homocysteine Study Am. J. Clinical Nutrition, August 1, 2007; 86(2): 514 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M Devlin, R. Clarke, J. Birks, J. G. Evans, and C. H Halsted Interactions among polymorphisms in folate-metabolizing genes and serum total homocysteine concentrations in a healthy elderly population Am. J. Clinical Nutrition, March 1, 2006; 83(3): 708 - 713. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
